Unknown

Dataset Information

0

Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis.


ABSTRACT: Carbapenems such as meropenem are being investigated for their potential therapeutic utility against highly drug-resistant tuberculosis. These ?-lactams target the transpeptidases that introduce interpeptide cross-links into bacterial peptidoglycan thereby controlling rigidity of the bacterial envelope. Treatment of Mycobacterium tuberculosis (Mtb) with the ?-lactamase inhibitor clavulanate together with meropenem resulted in rapid, polar, cell lysis releasing cytoplasmic contents. In Mtb it has been previously demonstrated that 3-3 cross-linkages [involving two diaminopimelate (DAP) molecules] predominate over 4-3 cross-linkages (involving one DAP and one D-alanine) in stationary-phase cells. We purified and analysed peptidoglycan from Mtb and found that 3-3 cross-linkages predominate throughout all growth phases and the ratio of 4-3/3-3 linkages does not vary significantly under any growth condition. Meropenem treatment was accompanied by a dramatic accumulation of unlinked pentapeptide stems with no change in the tetrapeptide pools, suggesting that meropenem inhibits both a D,D-carboxypeptidase and an L,D-transpeptidase. We purified a candidate D,D-carboxypeptidase DacB2 and showed that meropenem indeed directly inhibits this enzyme by forming a stable adduct at the enzyme active site. These results suggest that the rapid lysis of meropenem-treated cells is the result of synergistically inhibiting the transpeptidases that introduce 3,3-cross-links while simultaneously limiting the pool of available substrates available for cross-linking.

SUBMITTER: Kumar P 

PROVIDER: S-EPMC3468717 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis.

Kumar Pradeep P   Arora Kriti K   Lloyd John R JR   Lee Ill Y IY   Nair Vinod V   Fischer Elizabeth E   Boshoff Helena I M HI   Barry Clifton E CE  

Molecular microbiology 20120828 2


Carbapenems such as meropenem are being investigated for their potential therapeutic utility against highly drug-resistant tuberculosis. These β-lactams target the transpeptidases that introduce interpeptide cross-links into bacterial peptidoglycan thereby controlling rigidity of the bacterial envelope. Treatment of Mycobacterium tuberculosis (Mtb) with the β-lactamase inhibitor clavulanate together with meropenem resulted in rapid, polar, cell lysis releasing cytoplasmic contents. In Mtb it has  ...[more]

Similar Datasets

| S-EPMC3370771 | biostudies-literature
| S-EPMC2679150 | biostudies-other
| S-EPMC10052773 | biostudies-literature
| S-EPMC3750105 | biostudies-literature
| S-EPMC10989012 | biostudies-literature
| S-EPMC3448018 | biostudies-literature
| S-EPMC5487608 | biostudies-literature
| S-EPMC5913991 | biostudies-literature
| S-EPMC5453184 | biostudies-literature
| S-EPMC6262012 | biostudies-literature